skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Review

(3882) Views  (1464) Full article downloads

Authors: Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Published Date September 2009 Volume 2009:2 Pages 69 - 78
DOI: http://dx.doi.org/10.2147/PGPM.S5803

Robert Greene1, Shaymaa S Mousa, Mohamed Ardawi2, Mohamed Qari2, Shaker A Mousa1

1The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Center of Excellence in Osteoporosis Research, King Abdul Aziz University, Jeddah, Saudi Arabia

Abstract: Osteoporosis is a complicated and preventable disease with major morbidity complications that affects millions of people. In the last 15 years, there have been numerous studies and research in the new fields of pharmacogenetics and pharmacogenomics related to osteoporosis. Numerous “candidate genes” have been identified and have been found to be associated with osteoporosis as well as the treatment of osteoporosis. Many studies have found conflicting results on different polymorphisms and whether or not they are related to bone mineral density and osteoporosis. There is a need for larger and better designed pharmacogenomic studies related to osteoporosis incorporating a greater variety of candidate genes. The evaluation of osteoporosis and fracture risk is moving from a risk stratification approach to a more individualized approach, in which an individual’s absolute risk of fracture is evaluable as a constellation of the individual’s environmental exposure and genetic makeup. Therefore, the identification of gene variants associated with osteoporosis phenotypes or response to therapy might help individualize the prognosis, treatment, and prevention of fracture. This review focuses on major candidate genes and what needs to be done to take the genetics of osteoporosis and incorporate them into the pharmacogenomics of the management of osteoporosis.

Keywords: pharmacogenomics, osteoporosis, VDR, ER-alpha, CYP19 Gene, LRP5, COLIA1, polymorphisms, genetics






 

Other articles by Professor Shaker Mousa



Readers of this article also read:

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Individualization of antiretroviral therapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions